Literature DB >> 20670911

The Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) instrument was useful for refining a randomized trial design: experiences from an investigative team.

Daniel L Riddle1, Robert E Johnson, Mark P Jensen, Francis J Keefe, Kurt Kroenke, Matthew J Bair, Dennis C Ang.   

Abstract

OBJECTIVE: A recently published instrument (PRECIS) was designed to assist investigative teams in understanding the various design decisions that need to be made regarding pragmatic vs. explanatory trials. Our team used this instrument during an investigators' meeting to organize our discussion regarding the design of a planned trial and to determine the extent of consensus among the study investigators. STUDY DESIGN AND
SETTING: The study was descriptive in nature and occurred during an investigator meeting. After reading and reviewing the 10 PRECIS criteria, the team made quantitative judgments of the planned study regarding each PRECIS criteria to reflect initial, ideal, and final study design perceptions.
RESULTS: Data indicated that the final study design was more explanatory in nature than the preliminary plan. Evidence of consensus was obtained.
CONCLUSION: The investigative team found that applying PRECIS principles were useful for (1) detailing points of discussion related to trial design, (2) making revisions to the design to be consistent with the project goals, and (3) achieving consensus. We believe our experiences with PRECIS may prove valuable for trial researchers in much the same way that case reports can provide valuable insights for clinicians.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20670911      PMCID: PMC2943562          DOI: 10.1016/j.jclinepi.2010.03.006

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  8 in total

1.  Why we will remain pragmatists: four problems with the impractical mechanistic framework and a better solution.

Authors:  Andrew D Oxman; Carl Lombard; Shaun Treweek; Joel J Gagnier; Malcolm Maclure; Merrick Zwarenstein
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

2.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.

Authors:  Kevin E Thorpe; Merrick Zwarenstein; Andrew D Oxman; Shaun Treweek; Curt D Furberg; Douglas G Altman; Sean Tunis; Eduardo Bergel; Ian Harvey; David J Magid; Kalipso Chalkidou
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

3.  What kind of randomized trials do we need?

Authors:  Merrick Zwarenstein; Shaun Treweek
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

4.  The practicalists' response.

Authors:  Paul J Karanicolas; Victor M Montori; P J Devereaux; Holger Schünemann; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

5.  A pragmatic resolution.

Authors:  Andrew D Oxman; Carl Lombard; Shaun Treweek; Joel J Gagnier; Malcolm Maclure; Merrick Zwarenstein
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

6.  Explaining pragmatic trials to pragmatic policymakers.

Authors:  Malcolm Maclure
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

7.  Explanatory and pragmatic attitudes in therapeutical trials.

Authors:  D Schwartz; J Lellouch
Journal:  J Chronic Dis       Date:  1967-08

8.  A new 'mechanistic-practical" framework for designing and interpreting randomized trials.

Authors:  Paul J Karanicolas; Victor M Montori; P J Devereaux; Holger Schünemann; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2008-05-12       Impact factor: 6.437

  8 in total
  15 in total

1.  Are explanatory trials ethical? Shifting the burden of justification in clinical trial design.

Authors:  Kirstin Borgerson
Journal:  Theor Med Bioeth       Date:  2013-08

Review 2.  A systematic review of eHealth cancer prevention and control interventions: new technology, same methods and designs?

Authors:  Michael A Sanchez; Borsika A Rabin; Bridget Gaglio; Michelle Henton; M Khair Elzarrad; Peyton Purcell; Russell E Glasgow
Journal:  Transl Behav Med       Date:  2013-12       Impact factor: 3.046

3.  How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial.

Authors:  Peter Selby; Gerald Brosky; Paul I Oh; Vincent Raymond; Suzanne Ranger
Journal:  BMC Med Res Methodol       Date:  2012-07-23       Impact factor: 4.615

4.  The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.

Authors:  Daniel J Bratton; Andrew J Nunn; Fenella Wojnarowska; Gudula Kirtschig; Anna Sandell; Hywel C Williams
Journal:  Trials       Date:  2012-04-27       Impact factor: 2.279

5.  Similarities and differences between patients included and excluded from a randomized clinical trial of vitamin D supplementation for improving glucose tolerance in prediabetes: interpreting broader applicability.

Authors:  Yuval Eisenberg; Hiba Mohiuddin; Karthik Cherukupally; Hassan Zaidi; Subhash Kukreja; Elena Barengolts
Journal:  Trials       Date:  2015-07-15       Impact factor: 2.279

Review 6.  Differences between the real and the desired worlds in the results of clinical trials.

Authors:  Regina El Dib; Eliane Chaves Jorge; Amélia Kamegasawa; Solange Ramires Daher; Regina Stella Spagnuolo; Marise Pereira da Silva; Gabriel Pereira Braga; Enilze Volpato; Norma Sueli Pinheiro Módolo; Marluci Betini; Adriana do Valle; Ione Corrêa; Rodrigo Bazan; Ricardo Augusto M B Almeida; Silke Anna Theresa Weber; Silvana Molina; Hugo Yoo; Paulo Villas Boas; José Eduardo Corrente; Joseph Mathew; Anil Kapoor; Raíssa Carvalho; Roberto Bezerra Vital; Leandro Gobbo Braz; Paulo do Nascimento Junior
Journal:  Clinics (Sao Paulo)       Date:  2015-09       Impact factor: 2.365

7.  Partnership for fragility bone fracture care provision and prevention program (P4Bones): study protocol for a secondary fracture prevention pragmatic controlled trial.

Authors:  Isabelle Gaboury; Hélène Corriveau; Gilles Boire; François Cabana; Marie-Claude Beaulieu; Pierre Dagenais; Suzanne Gosselin; Earl Bogoch; Marie Rochette; Johanne Filiatrault; Sophie Laforest; Sonia Jean; Alvine Fansi; Diane Theriault; Bernard Burnand
Journal:  Implement Sci       Date:  2013-01-24       Impact factor: 7.327

8.  Racial Differences in Pain and Function Following Knee Arthroplasty: A Secondary Analysis From a Multicenter Randomized Clinical Trial.

Authors:  Daniel L Riddle; James Slover; Francis J Keefe; Dennis C Ang; Levent Dumenci; Robert A Perera
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-06       Impact factor: 5.178

9.  Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular Health Awareness Program (CHAP) trial as an illustrative example.

Authors:  Lehana Thabane; Janusz Kaczorowski; Lisa Dolovich; Larry W Chambers; Lawrence Mbuagbaw
Journal:  Trials       Date:  2015-09-02       Impact factor: 2.279

10.  Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.

Authors:  Kirsty Loudon; Merrick Zwarenstein; Frank Sullivan; Peter Donnan; Shaun Treweek
Journal:  Trials       Date:  2013-04-27       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.